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Abstract: In Tunisia, the ATRA era began in 1998 with the use, consecutively, of two regimens 
combining ATRA and an anthracycline with 
From  2004,  51  patients  with  confirmed  APL  either  by  t(15;17)  or  PML/RARA  were  treated 
according to the PETHEMA LPA 99 trial. Forty three patients achieved CR (86%). The remaining 
seven patients had early death (one died before treatment onset): four caused by differentiation 
syndrome  (DS)  and  three died  from  central  nervous  system  hemorrhage.  Multivariate  analysis 
revealed that female gender (P=0.045), baseline WBC> 10 G/L ( P=0.041) and serum creatinine >
1.4mg/dl ( P=0.021) were predictive of mortality during induction.  DS was observed in 16 patients 
(32%) after a median onset time of 15 days from treatment onset (range, 2
30 (P=0.01) remained independent predictor of DS. Occurrenc
predicted occurrence of DS (P=0.011) and was significantly associated with high BMI (p=0.003). 
With a median follow-up of  50 months, 5 year cumulative incidence of relapse, event free and 
overall survival were 4.7%, 74% and 78%, respectively.
Introduction: Acute  promyelocytic  leukemia  (APL) 
has now become the most curable of all subtypes of 
acute  myeloid  leukemia.  A  major  advance  was  the 
introduction of all-trans retinoic acid (ATRA), which 
induces  differentiation  of  the  leukemic 
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In Tunisia, the ATRA era began in 1998 with the use, consecutively, of two regimens 
combining ATRA and an anthracycline with cytarabine (APL93), and without cytarabine (LPA99). 
From  2004,  51  patients  with  confirmed  APL  either  by  t(15;17)  or  PML/RARA  were  treated 
according to the PETHEMA LPA 99 trial. Forty three patients achieved CR (86%). The remaining 
death (one died before treatment onset): four caused by differentiation 
syndrome  (DS)  and  three died  from  central  nervous  system  hemorrhage.  Multivariate  analysis 
revealed that female gender (P=0.045), baseline WBC> 10 G/L ( P=0.041) and serum creatinine >
1.4mg/dl ( P=0.021) were predictive of mortality during induction.  DS was observed in 16 patients 
(32%) after a median onset time of 15 days from treatment onset (range, 2–
independent predictor of DS. Occurrence of hypertensive peaks significantly 
predicted occurrence of DS (P=0.011) and was significantly associated with high BMI (p=0.003). 
up of  50 months, 5 year cumulative incidence of relapse, event free and 
4% and 78%, respectively.
Acute  promyelocytic  leukemia  (APL) 
has now become the most curable of all subtypes of 
.  A  major  advance  was  the 
trans retinoic acid (ATRA), which 
induces  differentiation  of  the  leukemic 
promyelocytes.
1-4 In combination with anthracyclines, 
cure  rates  of  75–80%  are  now  reported.
challenges however remain: reducing 
which remains at approximately 10%, and preventing 
relapses.
1–7 In Tunisia, the ATRA era begun in 1998 
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In Tunisia, the ATRA era began in 1998 with the use, consecutively, of two regimens 
cytarabine (APL93), and without cytarabine (LPA99). 
From  2004,  51  patients  with  confirmed  APL  either  by  t(15;17)  or  PML/RARA  were  treated 
according to the PETHEMA LPA 99 trial. Forty three patients achieved CR (86%). The remaining 
death (one died before treatment onset): four caused by differentiation 
syndrome  (DS)  and  three died  from  central  nervous  system  hemorrhage.  Multivariate  analysis 
revealed that female gender (P=0.045), baseline WBC> 10 G/L ( P=0.041) and serum creatinine >
1.4mg/dl ( P=0.021) were predictive of mortality during induction.  DS was observed in 16 patients 
–29). Body mass index ≥ 
e of hypertensive peaks significantly 
predicted occurrence of DS (P=0.011) and was significantly associated with high BMI (p=0.003). 
up of  50 months, 5 year cumulative incidence of relapse, event free and 
In combination with anthracyclines, 
80%  are  now  reported.
1–3Two 
challenges however remain: reducing early mortality, 
which remains at approximately 10%, and preventing 
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with  the  use,  consecutively,  of  two  regimens 
combining ATRA with an anthracycline and cytarabine 
(APL93),  and  an  anthracycline  without  cytarabine 
(LPA99). Prior to the advent of ATRA we had treated 
20 patients with morphologically recognized APL with 
a combination of cytarabine 200 mg/m
2 (days 1–7) and 
daunorubicin  45  mg/m
2 (days  1–3).  The  remission 
induction rate was 35.7%, the early death 42.8%, and 
overall survival 10% at 6 years (unpublished data). 
Between  1998  and  2004,  34  consecutive  patients 
with genetically confirmed APL from two hematology 
departments (University  Hospital of Tunis  and  Sfax) 
were treated with the European APL93 trial in which, 
induction  treatment  consisted  of  ATRA,  and 
Daunorubicin associated to  cytarabine .The complete 
remission rate was 82%. Four year event free survival, 
cumulative  incidence  of  relapse  (CIR)  and  overall 
survival were 63.4%, 14.2%, 69.7% respectively.
8
Since  2004,  51  genetically  confirmed  APL  have 
been treated by the PETHEMA LPA 99 trial avoiding 
cytarabine during induction and consolidation cycles in 
order  to  reduce  toxicity  without  increasing  the 
incidence  of  relapse.
2 We  already  reported  our 
preliminary experience with this protocol in 39 patients 
with relatively limited follow up.
9 We update here our 
results on 51 patients and with longer follow up.
Methods:  Eligibility  criteria  in  this  study  were  a 
diagnosis of APL with demonstration of the t(15;17) or 
PML/RARA  rearrangement. Treatment  schedule  was 
similar to that of the Spanish PETHEMA LPA99 trial: 
Induction  therapy  consisted  of  oral  ATRA  45 
mg/m
2/day  until  morphological  CR  and  intravenous 
idarubicin 12 mg/m
2 on days 2, 4, 6, and 8. For patients 
aged    20  years    or  younger,  the  ATRA  dose  was 
adjusted to 25 mg/m
2. Coagulopathy was treated with 
fresh-frozen  plasma  and  apheresis  platelets  with  the 
objective of maintaining platelet counts above 20G/l, 
prothrombin  time  >50%,  and  fibrinogen  >1  g/l. 
Heparin was not used. Prednisone (0.5 mg/kg/d, days 
1–15)  was  added  if  WBC  >10G/l  to  prevent 
differentiation  syndrome  (DS).  Diagnosis  of  DS,  in 
agreement with previous experiences, was based on the 
presence of at least three of the following clinical signs
and/or  symptoms  in  the  absence  of  alternative 
explanations:  fever,  weight  gain,  respiratory  distress, 
pulmonary  infiltrates,  pleural  or  pericardial  effusion, 
hypotension,  and  renal  failure.  Patients  with  four  or 
more of the above signs or symptoms or with a life-
threatening manifestation (respiratory failure requiring 
respiratory  assistance,  or  renal  failure  requiring 
dialysis) were classified as having severe DS.  Death 
was attributed to DS when it occurred in patients with a 
severe  form  without  alternative  explanation.  In  the 
presence  of  suspected  symptoms  of  DS,  ATRA  was 
transiently discontinued and dexamethasone 10 mg bid 
for 3 days or more was started. Sweet’s syndrome was 
defined  according  to  criteria  defined  by  von  den 
Driesch  with  histologic  finding  of  dermal  neutrophil 
infiltration.
10 The  diagnosis  of  pseudotumor  cerebri 
was  made  based  on  the  three  following  criteria: 
papilledema,  elevated  intracranial  pressure  with  a 
normal  cerebral  constituency,  and  normal  central 
nervous system imaging studies.
11 Scrotal  ulcerations 
were  considered  related  to  ATRA  if  there  was  no 
evidence for other possible diagnoses such as bacterial 
or viral infection.
12
Patients in CR received 3 risk-adapted consolidation 
courses.
13 Intermediate- and high-risk patients received 
ATRA (45 mg/m
2 per day for 15 days) combined with 
idarubicin 12 mg/m
2 per day for 2 consecutive days in 
the third course. Patients who were tested negative for 
PML/RARA at the end of consolidation were started 
on maintenance therapy with oral mercaptopurine (50 
mg/m
2 per  day),  oral  methotrexate  (15  mg/m
2  per 
week), and oral ATRA (45 mg/m
2 per day for 15 days 
every 3 months) during 2 years. Prognostic factors of 
the occurrence of DS were analysed with Pearson test 
for  dichotomous  variables,  and  a  logistic  regression 
technique  for  multivariate  analysis.  P  values of  0.05 
were considered to be significant. CIR, event free and 
overall survival were estimated by the Kaplan–Meier 
method.
Results: Between August 2004 and December  2010, 
51 patients with APL genetically confirmed by t(15;17) 
and/or PML/RARA were diagnosed in the Department 
of Hematology of Aziza Othmana University Hospital, 
Tunis, Tunisia. One patient died from CNS bleeding 
before  treatment  and  50  patients  received  induction 
therapy  according  to  the  PETHEMA  LPA99  trial.  
Median  time  from  the  first  symptom  to  confirmed 
diagnosis was 15 days (range, 2–90). The main initial 
clinical  symptoms  consisted  of  bleeding  (66%), 
infection  (21%),  anemia  (10%)  and  deep  venous 
thrombosis (2%). DIC was confirmed biologically in 
70%  of  patients.  Main  clinical  and  biological 
characteristics of the patients are shown in Table 1.
Induction therapy: 
Hematological  and  molecular  responses.  Of  the  50 
evaluable  patients,  43  achieved  CR  (86%).  The 
remaining seven patients had early death: four caused 
by  DS  and  three  died  from  CNS  hemorrhage.  By 
multivariate analysis female gender (P=0.045), baseline 
WBC  >  10  G/L  (P=0.041)  and  serum  creatinine  >
1.4mg/dl  (P=0.021)  were associated  with  lower    CR 
rate. At the end of induction, 33 (78.5 %) of the 42 
patients  tested  molecularly  for  PML/RARA  were 
positive.Mediterr J Hematol Infect Dis 2011; 3: Open Journal System
Table 1. Baseline characteristics of the study population
Age,median, (range)                                                     30 (4-71)
    < 20 y, n (%)                                                               15 (29.4)
    ≥ 20 y, n (%)                                                               36 (70.6)
Gender , n (%)
    Male                                                                            20 (39.2)
    Female                                                                         31 (60.8)
Baseline WBC, G/l, median (range)                         4.4 (0.6-123)                                    
   < 10, n (%)                                                                    33 (65)
   ≥ 10, n (%)                                                                    18 (35)
Platelet count, G/l, median (range)                             17 (1-70)
   < 40, n (%)                                                                    46 (80)                             
   ≥ 40, n (%)                                                                     5 (10)
Hemoglobin, g/L ,median, range                               76 (25-135)
Sanz Score,n (%)
     Low                                                                              2 (4)
     Intermediate                                                                31 (61)
     High                                                                           18 (35)
Morphology subtype, n (%)
     Hypergranular                                                             38 (75)
     Microgranular                                                             12 (23)
     Basophilic                                                                     1 (2)
Immunophenotyping, n (%)
     CD33+                                                                         48 (94.1)
     CD13+                                                                         49 (96)
     CD117+                                                                       29 (56.8)
     CD34-                                                                          45 (80.3)
     HLADR-                                                                      47 (92.1)
     CD2+                                                                             9 (17.6)
     CD56+                                                                           4 (7.8)
Karyotype , n (%)
    t(15,17) +ve                                                                      43
    t(15,17) –ve*                                                                      8
    t(15,17) with additional cytogenetic abnormalities          17
Molecular analysis
    PML/RARA , n (+ve, n)                                                50 (47)
    Isoforms , n (%)                                                                38
         Bcr 1                                                                          25 (65)
         Bcr 2                                                                            1 (3)
         Bcr 3                                                                          12 (32)    
*3 culture failure and 5 normal karyotype
                                                                                                                                                              
Differentiation  syndrome  and  other  ATRA-related 
complications. DS was observed in 16 patients (32%) 
after a median of 15 days from treatment onset (range, 
2-29) and median WBC (at the onset of DS) of 14.7 
G/L  (range,  0.7-82.7).  Clinical  symptoms  of  DS  are 
summarised in table 2.
A hypertensive peak was observed 24 to 96 hours
developed  DS,  of  whom  only  one  had  a  history  of 
(median 36)  before DS in 7 (43.7 %)  of the pts who
Table  2 Clinical  symptoms  observed  in  the  16  patients  who 
developed DS.
Symptoms of DS                                                  n (%)
         Fever                                                           11 (68.6)
         Dyspnea                                                      15 (93)
         Weight gain                                                  8 (50)
         Pulmonary infiltrates                                    9 (56)
         Pleural/Pericardial effusion                          6 (37.5)
         Hypotension                                                 3 (18.7)
         Renal failure                                               11 (68.6)
systemic hypertension. Systolic and diastolic blood
pressure values varied from 160 to 260 mmHg and 95 
to 110 mmHg, respectively. DS was severe in 11 cases,
moderate in 4, and fatal in four cases. By univariate 
analysis,  age  ≥  40  (P=0.034),  BMI  ≥  30  (P=0.009), 
baseline  WBC  ≥  10G/l  (p=0.034),  serum  creatinine 
>1.4mg  (p<0.001)  and  absence  of  cytogenetic 
abnormalities  in  addition  to  t(15;17)  (p=0.009)  were 
associated with DS. The last factor was not statistically 
related  to  other  DS  predictive  factors,  but  was 
significantly associated with a patient age greater than 
20 years (P=0.019). A hypertensive peak prior to DS 
was seen in 43.7% of the patients who developed DS 
compared  to  11.7%  of  those  without  DS  (P=0.011). 
Occurrence  of  a  hypertensive  peak  was  independent 
from the use of steroid prophylaxis (P=0.45), but was 
significantly associated with high BMI (P=0.003). By 
multivariate  analysis, BMI  remained  an  independent 
predictor of DS (P=0.01).
Other ATRA-related complications observed were: 
scrotal ulcerations in 4 patients, perineal ulceration in 1 
patient,  pseudotumor  cerebri  in  1  patient  (aged  32 
years),  spleen  infarction  in  1  patient,  and  Sweet’s 
syndrome in 2 patients.
Infectious complications. During the induction phase, 
hematologic recovery from neutropenia was observed 
at a median of 30 days (range, d19-d46) from start of 
chemotherapy.  Neutropenic febrile  episodes  were 
microbiologically  and  clinically  documented  in  25% 
and 18% of cases, respectively.




rd cycles was 11.5 days (range, 
5-26), 13 days (range 8-36) and 13 days (range, 2-34) 
respectively.  Febrile  neutropenia  occurred  in  38%, 
67.5% and 48% during the three consolidation courses, 
respectively.
Molecular response: Forty two patients were assessed
for molecular response after induction therapy and at 
the end of consolidation therapy. 33 (78.5%) and 42 
(100%)  were  PML/RARA  –ve  respectively  after 
induction and consolidation.
Maintenance  treatment:  All  42  patients  alive  after 
completing  consolidation therapy  proceeded  to 
maintenance  therapy.  Major  side  effects  observed 
during  this  phase  were  headaches  and  skin  dryness 
during ATRA therapy.
Outcome:  Median  follow-up  of  this  study  was  50 
months.  Forty  patients  were  alive  in  continuous 
complete remission. Two patients, aged 16 and 8 years, 
died  in  CR  from  septic  shock  during  the  third 
consolidation course and from cardiac failure, after 5 
and 15 months, respectively. Two relapses occurred in Mediterr J Hematol Infect Dis 2011; 3: Open Journal System
2 patients (13 and 30 years) of the intermediate risk 
group after 35 and 36 months of CR, respectively. The 
first patient (13 yr) was salvaged with two cycles of 
arsenic trioxide (ATO 0.15 mg/kg i.v. for 25 days) and 
ATRA (25 mg/m
2 bid until CR). This patient died from 
a subsequent relapse 47 months from diagnosis. The
second patient was salvaged with the LPA99 protocol 
and then received autologous stem cell transplantation 
in negative molecular status. He was 6 months from 
ASCT  with  negative  PML/RARA.  Two  patients  (41 
and  27  years)  developed  secondary  myelodysplastic 
syndrome with monosomy 7, 25 and 22 months after 
achieving CR, respectively. The first patient declined 
bone marrow transplantation and died 47 months from 
APL diagnosis. The second patient failed FLAG-ida as 
induction  chemotherapy  and  was  still  alive  in 
refractory  AML.  Five  year  cumulative  incidence  of 
relapse, event free survival and overall survival were 
4.7% (Figure 1), 74% (Figure 2) and 78% (Figure 3), 
respectively.
Discussion:  Our  results  show  that  trials  combining 
ATRA and anthracycline based chemotherapy (with or 
without AraC) designed in industrialized countries can 
be  used  at  full  dose in  a  country  with  more  limited 
resources like Tunisia, with CR rates greater than 80% 
(82% with APL93 trial, and 86% with LPA99 trial).
8,9
As in previous experiences, all failures to achieve CR 
were due to early death. Our 14% early death rate was 
however  somewhat  higher  than  in  recent  large 
industrialized country experiences, probably due in part 
to  the  higher proportion of Sanz’s  high score (35%) 
than  in  most  series,  and  also  to  Tunisia’s  socio 
economic  status,  as  median  interval  from  first 
symptoms to diagnosis was 15 days.
14 Early death in 
our study was due to hemorrhage (43%) and DS (57%)
Figure 1. Five year cumulative incidence of relapse
Figure 2. Five year event free survival
Figure 3. Five year  overall survival
compared to 58% for hemorrhage, 31% for infection, 
and 10% for DS in the Spanish experience.
14 The rate 
of early death did not decrease in LPA99 study, despite 
prophylactic  use  of  prednisone  (to  prevent  DS)  and 
tranexamic  acid  (to  improve  coagulopathy).  Renal 
dysfunction  (creatinine>1.4mg/dl)  and  high  WBC 
(>10G/L) were the only independent predictors of early 
death  in  the  PETHEMA  study.
14 Park  et  al.  in  an 
epidemiologic study of the rate of early death in US 
population-based  datasets of  all  newly  diagnosed 
patients with APL, suggested that the early death rate 
had  changed  only  modestly  since  1992  (22.7%  in 
1992–1996, and  18.1%  in  2002–2007),  and  was 
significantly  higher than  what  is  reported  in Mediterr J Hematol Infect Dis 2011; 3: Open Journal System
contemporary clinical trials.
15
The high incidence of DS in our experience could 
probably be explained by the high proportion (35%) of 
HR patients in our study, and more hypothetically by 
ethnic  differences  with  other  populations.  We  found 
higher baseline WBC and increased serum creatinine to 
be predictors of DS,
16 as in Spanish studies. We also 
confirmed the correlation between high BMI ≥ 30 and 
occurrence of DS, which we had found in a preliminary 
report  with  smaller  patient  numbers.
17 We  then 
suggested as a possible explanation to this link the fact 
that  leptin  receptors,  absent  from  normal 
promyelocytes  are  present  on  APL  cells.  Leptin 
secretion by bone marrow adipocytes in the vicinity of 
leukemic  cells  could  play  a  major  role  in  the 
proliferation and survival of APL cells leading to high 
risk of developing DS.
18,19
We noted hypertensive peak before DS in 43.7% of 
patients who developed this complication compared to 
11.7% of those without DS (P=0.011). Occurrence of a 
hypertensive  peak  was  independent  of  the  use  of 
steroid  prophylaxis,  but  was  significantly  associated 
with  high  BMI.  Increased  leptinemia  contributes  to 
increased  sympathic  activity  and  the  development of 
obesity-related hypotension. Leptin also increases the 
generation  of  reactive  oxygen  species  (ROS)  in 
endothelial  cells,  stimulates  secretion  of 
proinflammotory  cytokines such  as  TNF-b  and  IL-6, 
both  of  which  are  promoters  of  hypertension  and 
atherosclerosis,
20 possibly explaining the relationshsip 
between hypertensive peaks in obese patients prior to 
the onset of DS .This finding needs to be prospectively 
validated in a larger series. We also found that patients 
without  cytogenetic  abnormalities  in  addition  to 
t(15,17)  had  increased  risk  to  develop  DS,  although 
there is no clear explanation to his relationship. Four 
patients, who required   ventilation (3 cases) and renal 
dialysis (1 patient) died from severe DS .
In  our  study,  two  patients  developed  secondary 
MDS  with  monosomy  7,  a  relatively  high  incidence 
(4.7%)  compared  to  what  has  been  previously 
reported.
21,22,23
In conclusion despite more limited resources than in 
industrialized countries, and non availability of arsenic 
derivatives, our results are quite  acceptable. The  CR 
rate we observed is still somewhat inferior to what is 
reported  in  international  trials.  However  our  5  year 
EFS  and  OS  of  74%  and  78%  are  encouraging  and 
suggest  that  there  is  no  need  to  adapt  protocols  by 
reducing  dose-intensity  in  trials  in  developing 
countries.
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